Metagenomi, Inc. Files 2023 Annual Report on Form 10-K

Ticker: MGX · Form: 10-K · Filed: Mar 27, 2024 · CIK: 1785279

Metagenomi, Inc. 10-K Filing Summary
FieldDetail
CompanyMetagenomi, Inc. (MGX)
Form Type10-K
Filed DateMar 27, 2024
Risk Levellow
Pages15
Reading Time17 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Metagenomi, MGX, Annual Report, Emerging Growth Company

TL;DR

<b>Metagenomi, Inc. has filed its 2023 annual report, confirming its status as an emerging growth company and its listing on the Nasdaq.</b>

AI Summary

Metagenomi, Inc. (MGX) filed a Annual Report (10-K) with the SEC on March 27, 2024. Metagenomi, Inc. filed its annual report for the fiscal year ended December 31, 2023. The company is registered as a non-accelerated filer and an emerging growth company. Metagenomi, Inc. is incorporated in Delaware and its principal executive offices are located in Emeryville, California. The company's common stock trades on The Nasdaq Global Select Market under the ticker symbol MGX. Metagenomi, Inc. has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Metagenomi, Inc., this filing contains several important signals. This filing provides a comprehensive overview of Metagenomi's financial performance and operational status for the fiscal year 2023, crucial for investors assessing the company's trajectory. As an emerging growth company, Metagenomi may utilize extended transition periods for new accounting standards, which is a key consideration for understanding its financial reporting timeline.

Risk Assessment

Risk Level: low — Metagenomi, Inc. shows low risk based on this filing. The filing indicates Metagenomi is a non-accelerated filer and an emerging growth company, suggesting it is in an earlier stage of development with potentially less stringent reporting requirements compared to larger, established companies.

Analyst Insight

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to understand Metagenomi's business and prospects.

Key Numbers

  • 2023 — Fiscal Year End (Fiscal year ended December 31, 2023)
  • 2024-03-27 — Filing Date (Filed as of date)
  • 001-41949 — SEC File Number (Commission File Number)
  • 5959 Horton Street, 7th Floor — Principal Executive Office Address (Address of principal executive offices)
  • Nasdaq Global Select Market — Exchange (Name of each exchange on which registered)

Key Players & Entities

  • Metagenomi, Inc. (company) — Registrant
  • 2023 (date) — Fiscal year ended
  • December 31, 2023 (date) — Fiscal year ended
  • 001-41949 (other) — Commission File Number
  • Delaware (other) — State or other jurisdiction of incorporation
  • 81-3909017 (other) — I.R.S. Employer Identification No.
  • Emeryville, California (other) — Address of principal executive offices
  • MGX (other) — Trading Symbol

FAQ

When did Metagenomi, Inc. file this 10-K?

Metagenomi, Inc. filed this Annual Report (10-K) with the SEC on March 27, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Metagenomi, Inc. (MGX).

Where can I read the original 10-K filing from Metagenomi, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Metagenomi, Inc..

What are the key takeaways from Metagenomi, Inc.'s 10-K?

Metagenomi, Inc. filed this 10-K on March 27, 2024. Key takeaways: Metagenomi, Inc. filed its annual report for the fiscal year ended December 31, 2023.. The company is registered as a non-accelerated filer and an emerging growth company.. Metagenomi, Inc. is incorporated in Delaware and its principal executive offices are located in Emeryville, California..

Is Metagenomi, Inc. a risky investment based on this filing?

Based on this 10-K, Metagenomi, Inc. presents a relatively low-risk profile. The filing indicates Metagenomi is a non-accelerated filer and an emerging growth company, suggesting it is in an earlier stage of development with potentially less stringent reporting requirements compared to larger, established companies.

What should investors do after reading Metagenomi, Inc.'s 10-K?

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to understand Metagenomi's business and prospects. The overall sentiment from this filing is neutral.

How does Metagenomi, Inc. compare to its industry peers?

Metagenomi operates in the biotechnology sector, specifically focusing on biological products.

Are there regulatory concerns for Metagenomi, Inc.?

The company is subject to SEC reporting requirements under the Securities Exchange Act of 1934.

Industry Context

Metagenomi operates in the biotechnology sector, specifically focusing on biological products.

Regulatory Implications

The company is subject to SEC reporting requirements under the Securities Exchange Act of 1934.

What Investors Should Do

  1. Review Metagenomi's detailed financial statements for FY 2023.
  2. Analyze the risk factors section for potential business challenges.
  3. Understand the company's status as an emerging growth company and its implications.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the annual financial statements.
  • 2024-03-27: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the company's annual report for the fiscal year ended December 31, 2023, filed on March 27, 2024.

Filing Stats: 4,372 words · 17 min read · ~15 pages · Grade level 16.3 · Accepted 2024-03-27 08:44:41

Key Financial Figures

  • $0.0001 — ch registered Common stock, par value $0.0001 per share MGX The Nasdaq Global Sel

Filing Documents

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 83 Item 1B. Unresolved Staff Comments 135 Item 1C. Cybersecurity 135 Item 2.

Properties

Properties 136 Item 3.

Legal Proceedings

Legal Proceedings 136 Item 4. Mine Safety Disclosures 136 PART II Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 137 Item 6. [Reserved] 138 Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations 139 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 155 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 155 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 155 Item 9A.

Controls and Procedures

Controls and Procedures 155 Item 9B. Other Information 156 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 156 PART III Item 10. Directors, Executive Officers and Corporate Governance 157 Item 11.

Executive Compensation

Executive Compensation 160 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 167 Item 13. Certain Relationships and Related Transactions, and Director Independence 169 Item 14. Principal Accounting Fees and Services 170 PART IV Item 15. Exhibits, Financial Statement Schedules 172 Item 16. Form 10-K Summary 173 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains express or implied forward-looking statements that are based on our management&#x2019;s belief and assumptions and on information currently available to our management and which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about: &#x2022; the initiation, timing, progress and results of our research and development programs, preclinical studies and future clinical trials; &#x2022; our ability to demonstrate, and the timing of, preclinical proof-of-concept in vivo and ex vivo for multiple programs; &#x2022; our ability to advance any product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates; &#x2022; our ability to quickly leverage programs within our initial target indications and to pro

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.